VWA
ADAP

V Wealth Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

V Wealth Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$2K – 199
2017
Q2 		$2K Buy
+500
New +$2.61K ﹤0.01% 732

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

V Wealth Advisors's ADAP Position: Q3 2017 in Review

V Wealth Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q3 2017, closing a stake of 500 shares — an estimated $2K sold.

V Wealth Advisors first reported a position in ADAP in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 67 funds tracked by Wall St. Rank hold ADAP as of Q3 2017.

  • V Wealth Advisors reported no remaining Adaptimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
  • V Wealth Advisors sold 500 Adaptimmune Therapeutics shares in Q3 2017, an estimated $2K.
  • V Wealth Advisors first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 1 quarter.
  • V Wealth Advisors's Adaptimmune Therapeutics position peaked at $2K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.